Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy

Inhibitory antibodies to factor VIII (FVIII) are a major complication in the treatment of hemophilia A, affecting approximately 20% to 30% of patients. Current treatment for inhibitors is based on long-term, daily injections of large amounts of FVIII protein. Liver-directed gene therapy has been use...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Finn, Jonathan D., Ozelo, Margareth C., Sabatino, Denise E., Franck, Helen W. G., Merricks, Elizabeth P., Crudele, Julie M., Zhou, Shangzhen, Kazazian, Haig H., Lillicrap, David, Nichols, Timothy C., Arruda, Valder R.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2010
Schlagworte:
Gene Therapy
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3031380/
https://ncbi.nlm.nih.gov/pubmed/20876851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-06-288001
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge